IgG-immunoadsorptions and eculizumab combination in STEC-hemolytic and uremic syndrome pediatric patients with neurological involvement.
Eculizumab
IgG immunoadsorption
Neurological involvment
Pediatrics
STEC HUS
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
11
01
2024
accepted:
06
05
2024
revised:
08
04
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
aheadofprint
Résumé
Neurological complications pose a significant threat in pediatric hemolytic and uremic syndrome (HUS) resulting from infections with Shiga toxin-producing Escherichia coli (STEC), with no established treatment. The involvement of complement activation in the pathogenesis of STEC-HUS is acknowledged, and eculizumab (ECZ), a terminal complement blocker, has been documented in several pediatric series with inconsistent results. Antibody-mediated mechanisms have also been suggested, with IgG-immunoadsorption (IgIA) showing promise in adults with neurological complications. We aimed to assess the benefit of combining IgIA with ECZ in pediatric patients with neurological STEC-HUS compared to patients treated with ECZ alone or supportive care. Multicenter retrospective study conducted on pediatric patients (< 18 years) with neurological STEC-HUS treated with IgIA + ECZ or ECZ alone from 2010 to 2020 in France. A historical cohort treated with supportive care served as controls. Primary outcome included survival and neurological evaluation at 1-year follow-up (dichotomized as normal vs. abnormal). A total of 42 children were included: 18 treated with IgIA + ECZ, 24 with ECZ alone, and 27 with supportive care. Although there was no significant difference in survival between groups, three deaths occurred in the control group in the acute phase, while none was reported in both the IgIA + ECZ and ECZ alone groups, despite presenting with more severe neurological symptoms for IgIA + ECZ patients. No significant association was found between treatment group and 1-year neurological evaluation after adjustment for age, sex, and initial neurological presentation. Systematic association of IgIA + ECZ is not supported for all neurological STEC-HUS pediatric patients; potential rescue therapy for severe cases warrants consideration.
Sections du résumé
BACKGROUND
BACKGROUND
Neurological complications pose a significant threat in pediatric hemolytic and uremic syndrome (HUS) resulting from infections with Shiga toxin-producing Escherichia coli (STEC), with no established treatment. The involvement of complement activation in the pathogenesis of STEC-HUS is acknowledged, and eculizumab (ECZ), a terminal complement blocker, has been documented in several pediatric series with inconsistent results. Antibody-mediated mechanisms have also been suggested, with IgG-immunoadsorption (IgIA) showing promise in adults with neurological complications. We aimed to assess the benefit of combining IgIA with ECZ in pediatric patients with neurological STEC-HUS compared to patients treated with ECZ alone or supportive care.
METHODS
METHODS
Multicenter retrospective study conducted on pediatric patients (< 18 years) with neurological STEC-HUS treated with IgIA + ECZ or ECZ alone from 2010 to 2020 in France. A historical cohort treated with supportive care served as controls. Primary outcome included survival and neurological evaluation at 1-year follow-up (dichotomized as normal vs. abnormal).
RESULTS
RESULTS
A total of 42 children were included: 18 treated with IgIA + ECZ, 24 with ECZ alone, and 27 with supportive care. Although there was no significant difference in survival between groups, three deaths occurred in the control group in the acute phase, while none was reported in both the IgIA + ECZ and ECZ alone groups, despite presenting with more severe neurological symptoms for IgIA + ECZ patients. No significant association was found between treatment group and 1-year neurological evaluation after adjustment for age, sex, and initial neurological presentation.
CONCLUSIONS
CONCLUSIONS
Systematic association of IgIA + ECZ is not supported for all neurological STEC-HUS pediatric patients; potential rescue therapy for severe cases warrants consideration.
Identifiants
pubmed: 39297957
doi: 10.1007/s00467-024-06418-1
pii: 10.1007/s00467-024-06418-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H (1985) The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:775–782
pubmed: 3886804
doi: 10.1093/infdis/151.5.775
Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073–1086
pubmed: 15781103
Siegler RL (1995) The hemolytic uremic syndrome. Pediatr Clin North Am 42:1505–1529
pubmed: 8614598
doi: 10.1016/S0031-3955(16)40096-9
Sheth KJ, Swick HM, Haworth N (1986) Neurological involvement in hemolytic-uremic syndrome. Ann Neurol 19:90–93
pubmed: 3947042
doi: 10.1002/ana.410190120
Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT (2006) Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 117:1656–1662
pubmed: 16651320
doi: 10.1542/peds.2005-0785
Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-Höller D, Würzner R, Karch H, German-Austrian HUS Study Group (2012) Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 54:1413–1421
pubmed: 22412065
doi: 10.1093/cid/cis196
Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS (2013) Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28:2097–2105
pubmed: 23288350
doi: 10.1007/s00467-012-2383-6
Monet-Didailler C, Godron-Dubrasquet A, Madden I, Delmas Y, Llanas B, Harambat J (2019) Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort. Pediatr Nephrol 34:657–662
pubmed: 30368614
doi: 10.1007/s00467-018-4131-z
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181
pubmed: 23738544
doi: 10.1056/NEJMoa1208981
Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061–1073
pubmed: 25651368
pmcid: 4424817
doi: 10.1038/ki.2014.423
Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84–93
pubmed: 27012908
doi: 10.1053/j.ajkd.2015.12.034
Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701–711
pubmed: 26880462
doi: 10.1016/j.kint.2015.11.026
Monnens L, Molenaar J, Lambert PH, Proesmans W, van Munster P (1980) The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 13:168–171
pubmed: 7379368
Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1920–1924
pubmed: 19820137
pmcid: 2798880
doi: 10.2215/CJN.02730409
Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182:6394–6400
pubmed: 19414792
doi: 10.4049/jimmunol.0900151
Ståhl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503–5513
pubmed: 21447825
doi: 10.1182/blood-2010-09-309161
Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C (2011) Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187:172–180
pubmed: 21642543
doi: 10.4049/jimmunol.1100491
Ahlenstiel-Grunow T, Hachmeister S, Bange FC et al (2016) Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome. Nephrol Dial Transplant 31:1114–1121
pubmed: 27190382
doi: 10.1093/ndt/gfw078
Brady TM, Pruette C, Loeffler LF, Weidemann D, Strouse JJ, Gavriilaki E, Brodsky RA (2016) Typical HUS: evidence of acute phase complement activation from a daycare outbreak. J Clin Exp Nephrol 1:11
pubmed: 27413789
pmcid: 4940046
doi: 10.21767/2472-5056.100011
Karnisova L, Hradsky O, Blahova K et al (2018) Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study. Eur J Pediatr 177:1837–1844
pubmed: 30251107
doi: 10.1007/s00431-018-3255-2
Ferraris JR, Ferraris V, Acquier AB et al (2015) Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exp Immunol 181:118–125
pubmed: 25677399
pmcid: 4469161
doi: 10.1111/cei.12601
Netti GS, Santangelo L, Paulucci L et al (2020) Low C3 serum levels predict severe forms of STEC-HUS with neurologic involvement. Front Med (Lausanne) 7:357
pubmed: 32671083
doi: 10.3389/fmed.2020.00357
Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561–2563
pubmed: 21612462
doi: 10.1056/NEJMc1100859
Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nürnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R, Collaborators of the DGfN STEC-HUS registry (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807–3815
pubmed: 23114903
doi: 10.1093/ndt/gfs394
Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmüller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Münte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schöcklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhöner P, Wiesner M, Zeissig S, Büning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565
pubmed: 22815429
pmcid: 3400392
doi: 10.1136/bmj.e4565
Walsh PR, Johnson S (2019) Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 34:1485–1492
pubmed: 30058046
doi: 10.1007/s00467-018-4025-0
Loos S, Aulbert W, Hoppe B et al (2017) Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104:H4. Clin Infect Dis 64:1637–1643
pubmed: 28329394
doi: 10.1093/cid/cix218
Loos S, Ahlenstiel T, Kranz B et al (2012) An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 55:753–759
pubmed: 22670043
doi: 10.1093/cid/cis531
Delmas Y, Vendrely B, Clouzeau B et al (2014) Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 29:565–572
pubmed: 24293658
doi: 10.1093/ndt/gft470
Monet-Didailler C, Chevallier A, Godron-Dubrasquet A et al (2020) Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant 35:2147–2153
pubmed: 31411695
doi: 10.1093/ndt/gfz158
Keenswijk W, Raes A, Vande Walle J (2018) Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 177:311–318
pubmed: 29288280
doi: 10.1007/s00431-017-3077-7
Garnier A, Brochard K, Kwon T et al (2023) Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial. J Am Soc Nephrol 34:1561–1573
pubmed: 37303085
pmcid: 10482062
doi: 10.1681/ASN.0000000000000182
Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Müller L, King LA, Rosner B, Buchholz U, Stark K, Krause G, HUS Investigation Team (2011) Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 365:1771–1780
pubmed: 21696328
doi: 10.1056/NEJMoa1106483
Greinacher A, Friesecke S, Abel P et al (2011) Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 378:1166–1173
pubmed: 21890192
doi: 10.1016/S0140-6736(11)61253-1
Combe C, Bui HN, de Précigout V, Hilbert G, Delmas Y (2012) Immunoadsorption in patients with haemolytic uraemic syndrome. Lancet 379:517–518 (author reply 518-519)
pubmed: 22325656
doi: 10.1016/S0140-6736(12)60228-1
Stummvoll GH (2011) Immunoadsorption (IAS) for systemic lupus erythematosus. Lupus 20:115–119
pubmed: 21303827
doi: 10.1177/0961203310389487
Klingel R, Heibges A, Fassbender C (2009) Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives. Atheroscler Suppl 10:129–132
pubmed: 20129391
doi: 10.1016/S1567-5688(09)71827-6
Pietrement C, Bednarek N, Baudouin V, Fila M, Deschênes G (2012) Immunoadsorption for paediatric post-diarrhoea haemolytic-uraemic syndrome with severe neurological involvement. Clin Kidney J 5:484–485
pubmed: 26019834
pmcid: 4432409
doi: 10.1093/ckj/sfs090
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637
pubmed: 19158356
pmcid: 2653687
doi: 10.1681/ASN.2008030287
Pape L, Hartmann H, Bange FC et al (2015) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 94:e1000
pubmed: 26091445
doi: 10.1097/MD.0000000000001000
Saini A, Emke AR, Silva MC, Perlman SJ (2015) Response to eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations. Clin Pediatr (Phila) 54:387–389
pubmed: 24817079
doi: 10.1177/0009922814534520
Gitiaux C, Krug P, Grevent D et al (2013) Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 55:758–765
pubmed: 23659643
doi: 10.1111/dmcn.12161
Ekinci Z, Candan C, Alpay H et al (2013) Hemolytic uremic syndrome outbreak in Turkey in 2011. Turk J Pediatr 55:246–252
pubmed: 24217069
Nathanson S, Kwon T, Elmaleh M et al (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5:1218–1228
pubmed: 20498239
pmcid: 2893076
doi: 10.2215/CJN.08921209
Scheiring J, Andreoli SP, Zimmerhackl LB (2008) Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 23:1749–1760
pubmed: 18704506
pmcid: 6901419
doi: 10.1007/s00467-008-0935-6
Gianviti A, Perna A, Caringella A, Edefonti A, Penza R, Remuzzi G, Rizzoni G (1993) Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kidney Dis 22:264–266
pubmed: 8352251
doi: 10.1016/S0272-6386(12)70316-5
Ardissino G, Daccò V, Testa S, Civitillo CF, Tel F, Possenti I, Belingheri M, Castorina P, Bolsa-Ghiringhelli N, Tedeschi S, Paglialonga F, Salardi S, Consonni D, Zoia E, Salice P, Chidini G (2015) Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol 30:345–352
pubmed: 25149851
doi: 10.1007/s00467-014-2918-0